Pathobiology of Obesity¶
Chapter 413 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Obesity is defined as excess adipose tissue mass with adverse health effects, measured via BMI ( ≥ 30 kg/m²) and waist-to-hip ratio (>0.9 in women, >1.0 in men).
- Genetic factors account for ~50% of obesity risk, with MC4R mutations being the most common monogenic cause (1 in 300 population frequency).
- Leptin resistance, not deficiency, is the primary mechanism linking adiposity to metabolic dysfunction, with inflammation and ectopic fat storage as key mediators.
- Environmental factors like energy-dense diets, sedentary lifestyles, and obesogenic environments contribute to ~90% of obesity cases.
- Genetic syndromes (e.g., Prader-Willi, Bardet-Biedl) account for 2–5% of severe obesity cases, often with neurodevelopmental comorbidities.
1. DEFINITION & OVERVIEW¶
Obesity is a state of excess adipose tissue mass that adversely affects health. Body Mass Index (BMI) is the primary clinical measure (weight/height² in kg/m²), with WHO defining obesity as ≥ 30 kg/m² and overweight as 25–29.9 kg/m². Waist-to-hip ratio (>0.9 in women, >1.0 in men) reflects visceral fat distribution and metabolic risk.
Table 413-1: Classical Genetic Obesity Syndromes¶
| SYNDROME | INHERITANCE | ADDITIONAL CLINICAL FEATURES |
|---|---|---|
| Prader-Willi | Autosomal dominant | Hypotonia, failure to thrive, developmental delay, hypogonadotropic hypogonadism, hyperphagia, obesity |
| Bardet-Biedl | Autosomal recessive | Syndactyly/brachydactyly, developmental delay, retinal dystrophy, hypogonadism, renal abnormalities |
| Carpenter’s | Autosomal recessive | Acrocephaly, brachydactyly, developmental delay, congenital heart defects, growth retardation, hypogonadism |
| Tubby | Autosomal recessive | Progressive cone-rod dystrophy, hearing loss, obesity, hypogonadism |
1.1 BMI Classification¶
Underweight: <18.5; Normal weight: 18.5–24.9; Overweight: 25–29.9; Obese: ≥ 30.0. BMI thresholds vary by ethnicity, with lower thresholds associated with adverse outcomes in non-white populations.
1.2 Fat Distribution¶
Visceral (intra-abdominal) fat is more metabolically active than subcutaneous fat. Waist-to-hip ratio >0.9 in women and >1.0 in men is linked to increased risk of type 2 diabetes and dyslipidemia.
2. EPIDEMIOLOGY¶
In 2017–2018, 42.4% of U.S. adults aged ≥ 20 years had obesity. Non-Hispanic Black individuals had highest prevalence (49.6%), followed by Hispanic (44.8%), non-Hispanic White (42.2%), and non-Hispanic Asian (17.4%). Global obesity prevalence tripled since 1975; 1.9 billion adults were overweight in 2016 (650 million obese). Childhood obesity: 38 million children <5 years old were overweight or obese in 2019.
2.1 Ethnic Disparities¶
Obesity prevalence varies by ethnicity, with higher rates in Black and Hispanic populations. Asians show heterogeneity, with higher obesity rates in women (56.9% in Black women).
2.2 Temporal Trends¶
U.S. obesity prevalence rose from 14.5% (1976–1980) to 42.4% (2017–2018). Global obesity prevalence increased 3-fold since 1975, with 39% of adults overweight and 13% obese in 2016.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Obesity results from energy imbalance (excess intake > expenditure) with genetic, hormonal, and environmental factors. Key mechanisms include leptin resistance, inflammatory adipose tissue, and ectopic fat deposition. The hypothalamus regulates energy balance via leptin, POMC, and MC4R pathways.
Table 413-2: Obesity Syndromes due to Gene Mutations¶
| GENE AFFECTED | INHERITANCE | ADDITIONAL CLINICAL FEATURES |
|---|---|---|
| Leptin | Autosomal recessive | Severe hyperphagia, frequent infections, hypogonadotropic hypogonadism, mild hypothyroidism |
| Proopiomelanocortin | Autosomal recessive | Hyperphagia, cholestatic jaundice, adrenal crisis, pale skin, red hair |
| Carboxypeptidase E | Autosomal recessive | Severe insulin resistance, postprandial hypoglycemia |
| Single-minded 1 | Autosomal dominant | Hyperphagia, accelerated linear growth, speech delay, autistic traits |
| TrkB | Autosomal dominant | Hyperphagia, speech delay, hyperactivity, behavioral problems |
3.1 Hormonal Regulation¶
Leptin suppresses appetite and increases energy expenditure. MC4R mutations (most common monogenic cause) lead to hyperphagia and early-onset obesity. Insulin resistance in liver and muscle drives compensatory hyperinsulinemia.
3.2 Inflammatory Pathways¶
Obese adipose tissue has increased macrophage infiltration and inflammatory cytokines (TNF- α , IL-6), contributing to systemic inflammation and insulin resistance. Ectopic fat in liver, muscle, and pancreas disrupts metabolic homeostasis.
4. CLINICAL FEATURES¶
Obesity is associated with metabolic syndrome (dyslipidemia, insulin resistance, hypertension), cardiovascular disease, and musculoskeletal disorders. Complications include type 2 diabetes, NAFLD, obstructive sleep apnea, and certain cancers (endometrium, colon, pancreas).
4.1 Metabolic Complications¶
Dyslipidemia (high triglycerides, low HDL), hyperinsulinemia, and NAFLD are common. Insulin resistance in liver and muscle leads to compensatory hyperinsulinemia and hepatic glucose production.
4.2 Cardiovascular Risks¶
Obesity increases risk of hypertension, ischemic heart disease, and stroke. Visceral fat contributes to endothelial dysfunction and systemic inflammation.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include endocrine disorders (hypothyroidism, Cushing’s syndrome), hypothalamic tumors, and genetic syndromes (Prader-Willi, Bardet-Biedl). Secondary obesity must be distinguished from primary obesity via hormonal testing and imaging.
5.1 Endocrine Causes¶
Hypothyroidism (elevated TSH), Cushing’s syndrome (central obesity, striae), and hypercortisolism (24-h urine cortisol, dexamethasone suppression test).
5.2 Genetic Syndromes¶
Prader-Willi (hypotonia, hyperphagia), Bardet-Biedl (polydactyly, retinal dystrophy), and Albright’s hereditary osteodystrophy (short stature, obesity, skeletal defects).
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis involves BMI measurement, waist-to-hip ratio, and exclusion of secondary causes. Genetic testing is indicated for severe obesity with developmental delay. Hormonal assays (leptin, TSH, cortisol) and imaging (MRI for hypothalamic tumors) are used to identify underlying pathologies.
6.1 Laboratory Tests¶
Fasting glucose, HbA1c, lipid profile, TSH, cortisol (24-h urine or dexamethasone suppression test), and inflammatory markers (CRP, TNF- α ).
6.2 Imaging¶
Abdominal ultrasound for NAFLD, MRI for hypothalamic tumors, and CT for visceral fat quantification.
7. MANAGEMENT & TREATMENT¶
Management includes lifestyle modification (diet, exercise), pharmacotherapy (GLP-1 agonists, SGLT2 inhibitors), and bariatric surgery. Genetic obesity syndromes may require targeted therapies (e.g., setmelanotide for MC4R mutations).
7.1 Pharmacologic Therapy¶
GLP-1 agonists (liraglutide, semaglutide), SGLT2 inhibitors (dapagliflozin), and appetite suppressants (phentermine-topiramate). Setmelanotide for MC4R-deficient obesity.
7.2 Bariatric Surgery¶
Indicated for BMI ≥ 40 or ≥ 35 with comorbidities. Options include Roux-en-Y gastric bypass and sleeve gastrectomy. Risks include malnutrition and surgical complications.
8. PROGNOSIS & COMPLICATIONS¶
Obesity is associated with increased mortality from cardiovascular disease, cancer, and metabolic complications. Long-term risks include type 2 diabetes, NAFLD, and musculoskeletal disorders. Weight regain is common after dieting due to metabolic adaptation.
8.1 Mortality Risk¶
Obesity increases all-cause mortality by 50–100% in severe cases. Comorbidities like diabetes and cardiovascular disease significantly worsen prognosis.
9. SPECIAL CONSIDERATIONS¶
Obesity management in pregnancy requires careful monitoring to prevent gestational diabetes and preterm labor. In children, growth hormone therapy is used for Prader-Willi syndrome. Elderly patients face higher risks of frailty and surgical complications.
9.1 Pregnancy¶
Obesity in pregnancy increases risks of gestational diabetes, preeclampsia, and cesarean delivery. Weight management should focus on maternal and fetal safety.
9.2 Pediatrics¶
Childhood obesity is linked to metabolic syndrome and psychosocial issues. Treatment emphasizes lifestyle modification and family involvement.
10. KEY POINTS & CLINICAL PEARLS¶
- BMI ≥ 30 defines obesity, but ethnic variations exist. 2. MC4R mutations are the most common monogenic cause. 3. Leptin resistance, not deficiency, drives metabolic dysfunction. 4. Environmental factors account for ~90% of obesity cases. 5. Genetic testing is critical for severe obesity with developmental delay. 6. Bariatric surgery is effective for BMI ≥ 40 with comorbidities.